Vapotherm (NYSE:VAPO) Price Target Cut to $12.00

Vapotherm (NYSE:VAPOGet Rating) had its target price decreased by analysts at Canaccord Genuity Group from $21.00 to $12.00 in a report released on Wednesday, Benzinga reports. The firm currently has a “buy” rating on the stock. Canaccord Genuity Group’s price target would suggest a potential upside of 96.40% from the stock’s previous close.

Several other equities analysts also recently commented on the stock. Zacks Investment Research upgraded shares of Vapotherm from a “sell” rating to a “hold” rating in a report on Wednesday, April 6th. Canaccord Genuity Group cut their price target on shares of Vapotherm from $35.00 to $21.00 in a report on Friday, February 25th. Finally, Piper Sandler cut shares of Vapotherm from an “overweight” rating to an “underweight” rating and lowered their price objective for the company from $23.00 to $8.00 in a research report on Thursday, April 7th. Two equities research analysts have rated the stock with a sell rating and three have given a buy rating to the stock. According to, the stock currently has a consensus rating of “Hold” and a consensus target price of $20.00.

Shares of NYSE VAPO opened at $6.11 on Wednesday. The company has a market capitalization of $159.99 million, a price-to-earnings ratio of -2.66 and a beta of -1.07. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.70 and a current ratio of 2.54. The company has a 50 day simple moving average of $13.66 and a two-hundred day simple moving average of $18.11. Vapotherm has a fifty-two week low of $5.99 and a fifty-two week high of $31.87.

Vapotherm (NYSE:VAPOGet Rating) last issued its quarterly earnings results on Thursday, February 24th. The company reported ($0.71) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.62) by ($0.09). The business had revenue of $22.24 million for the quarter, compared to analysts’ expectations of $17.39 million. Vapotherm had a negative return on equity of 68.51% and a negative net margin of 52.78%. The company’s revenue was down 45.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.51) EPS. On average, analysts forecast that Vapotherm will post -2.5 earnings per share for the current fiscal year.

A number of institutional investors have recently added to or reduced their stakes in VAPO. Dark Forest Capital Management LP purchased a new stake in shares of Vapotherm in the 3rd quarter worth approximately $48,000. Macquarie Group Ltd. lifted its position in shares of Vapotherm by 211.6% in the 3rd quarter. Macquarie Group Ltd. now owns 2,315 shares of the company’s stock worth $52,000 after purchasing an additional 1,572 shares during the period. BNP Paribas Arbitrage SA lifted its position in shares of Vapotherm by 362.2% in the 3rd quarter. BNP Paribas Arbitrage SA now owns 4,160 shares of the company’s stock worth $93,000 after purchasing an additional 3,260 shares during the period. Royal Bank of Canada lifted its position in shares of Vapotherm by 40.0% in the 2nd quarter. Royal Bank of Canada now owns 4,332 shares of the company’s stock worth $103,000 after purchasing an additional 1,237 shares during the period. Finally, Advisor Group Holdings Inc. lifted its position in shares of Vapotherm by 261.0% in the 4th quarter. Advisor Group Holdings Inc. now owns 7,968 shares of the company’s stock worth $166,000 after purchasing an additional 5,761 shares during the period. 72.20% of the stock is owned by institutional investors.

About Vapotherm (Get Rating)

Vapotherm, Inc, a medical technology company, focuses on the development and commercialization of proprietary high velocity therapy products used to treat patients of various ages suffering from respiratory distress in the United States and internationally. The company offers precision flow systems, such as Precision Flow Hi-VNI, Precision Flow Plus, Precision Flow Classic, and Precision Flow Heliox that deliver heated, humidified, and oxygenated air at a high velocity to patients through a small-bore nasal interface.

Featured Stories

Receive News & Ratings for Vapotherm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vapotherm and related companies with's FREE daily email newsletter.